We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diabetic Screening Performed in Dental Setting

By LabMedica International staff writers
Posted on 01 Mar 2012
Print article
Oral blood samples drawn from deep pockets of periodontal inflammation can be used to measure glycated hemoglobin (HbA1c) an important gauge of a patient's diabetes status.

HbA1c is widely used to test for diabetes and blood glucose measured from oral blood compare well to those from finger-stick blood where an HbA1c reading of 6.5% or more indicates a value in the diabetic range.

At the New York University (NY, USA) a nursing and dental team of scientists compared HbA1c levels in paired samples of oral gingival crevicular blood (GCB) and finger-stick blood (FSB) taken from patients with periodontal disease. The oral blood was from patients with adequate bleeding on probing and was collected on special blood collection cards.

The blood samples were analyzed for HbA1c using the BioRad Variant II Analyzer (BioRad; Hercules, CA, USA), which employs high-performance liquid chromatography, and exclusively uses BioRad Reagents. A total of 120 individuals were eligible and participated in the study and provided a FSB sample for HbA1c testing. Average FSB HbA1c readings were 6.0% ± 0.83% with 20 in the diabetes range. An additional 66 patients had FSB HbA1c test results in the prediabetes range, which is between 5.7% and 6.4%, and are at increased risk of developing diabetes in the future.

Oral blood samples were also collected from 102 of the 120 participants; no bleeding on probing or insufficient bleeding to cover adequately the tip of the blood collection wand prevented collection and/or laboratory analysis of GCB samples from the remaining 18 participants. In the case of 27 of the 102 GCB samples, an unidentified component was observed to co-elute within the elution window of HbA1c in the laboratory. The presence of a co-elution peak from this unidentified component interfered with the quantification of HbA1c and generally resulted in underestimation of true HbA1c percentages. Therefore, only 75 patients' blood samples could be compared with both tests.

Of these 75 participants, 15 had FSB HbA1c values in the diabetes range of equal to or greater than 6.5%, including 8 who indicated that they had never been told by a health care provider that they had diabetes. For these 75 participants, the correlation between FSB and GCB HbA1c values was very high. Sheila M. Strauss, PhD, the principal author said, "In light of these findings, the dental visit could be a useful opportunity to conduct an initial diabetes screening, an important first step in identifying those patients who need further testing to determine their diabetes status". The study was published online on November 16, 2011 in the Journal of Periodontology.

Related Links:

New York University
BioRad


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.